Moderna up on COVID-19 vaccine data; plans to file for EUA today

 

• Moderna (NASDAQ:MRNA) jumps 10% in premarket in reaction to primary efficacy analysis data from Phase 3 study of its COVID-19 vaccine candidate, mRNA-1273 demonstrating efficacy of 94.1%, while vaccine efficacy against severe COVID-19 was 100%.
• Continuous review of safety data is ongoing and no new serious safety concerns have been identified.
• Primary analysis was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus 11 cases observed in the mRNA-1273 group. There was one COVID-19-related death in the study to date, which occurred in the placebo group.
• Today, the company will file for US Emergency Use Authorization (EUA), as well as apply for a conditional marketing authorization with the European Medicines Agency.
• In reaction to the news, Pfizer (NYSE:PFE) is up 2% while BioNTech (NASDAQ:BNTX) is +3%.
• https://seekingalpha.com/news/3639868-modernaplus-10-on-covidminus-19-vaccine-data-plans-to-file-for-eua-today